Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:ARCT NASDAQ:MRVI NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$23.90+2.2%$20.87$17.03▼$31.26$1.04B0.97428,038 shs392,763 shsARCTArcturus Therapeutics$9.13+8.6%$7.87$5.85▼$24.17$239.04M2.43344,367 shs412,637 shsMRVIMaravai LifeSciences$3.94+2.3%$3.32$1.95▼$4.11$989.71M0.621.74 million shs3.56 million shsPHATPhathom Pharmaceuticals$12.67+0.6%$11.57$2.21▼$18.31$1.00B0.571.50 million shs909,189 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+2.18%+10.49%+16.13%-16.52%+0.21%ARCTArcturus Therapeutics+8.56%+8.69%+11.07%+30.06%-18.77%MRVIMaravai LifeSciences+2.34%+13.22%+33.56%+27.51%+93.14%PHATPhathom Pharmaceuticals+0.56%+7.56%+12.62%+2.10%+427.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$23.90+2.2%$20.87$17.03▼$31.26$1.04B0.97428,038 shs392,763 shsARCTArcturus Therapeutics$9.13+8.6%$7.87$5.85▼$24.17$239.04M2.43344,367 shs412,637 shsMRVIMaravai LifeSciences$3.94+2.3%$3.32$1.95▼$4.11$989.71M0.621.74 million shs3.56 million shsPHATPhathom Pharmaceuticals$12.67+0.6%$11.57$2.21▼$18.31$1.00B0.571.50 million shs909,189 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+2.18%+10.49%+16.13%-16.52%+0.21%ARCTArcturus Therapeutics+8.56%+8.69%+11.07%+30.06%-18.77%MRVIMaravai LifeSciences+2.34%+13.22%+33.56%+27.51%+93.14%PHATPhathom Pharmaceuticals+0.56%+7.56%+12.62%+2.10%+427.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.11Hold$27.4314.76% UpsideARCTArcturus Therapeutics 2.69Moderate Buy$29.50223.11% UpsideMRVIMaravai LifeSciences 2.40Hold$5.3836.42% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.0097.32% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, AMPH, MRVI, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026ARCTArcturus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/8/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $23.003/27/2026PHATPhathom Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$16.00 ➝ $18.003/18/2026ARCTArcturus Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$22.003/17/2026ARCTArcturus Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/5/2026ARCTArcturus Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $21.003/4/2026ARCTArcturus Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$7.00 ➝ $8.003/4/2026ARCTArcturus Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$72.00 ➝ $25.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.48$4.35 per share5.50$17.17 per share1.39ARCTArcturus Therapeutics$82.03M3.16N/AN/A$7.53 per share1.21MRVIMaravai LifeSciences$185.74M5.45$0.43 per share9.20$1.46 per share2.70PHATPhathom Pharmaceuticals$175.11M5.77N/AN/A($4.22) per share-3.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$2.0311.777.311.8913.63%17.58%8.27%5/7/2026 (Estimated)ARCTArcturus Therapeutics-$65.78M-$2.38N/AN/AN/A-80.19%-29.13%-22.03%5/7/2026 (Confirmed)MRVIMaravai LifeSciences-$130.77M-$0.90N/AN/AN/A-70.40%-22.79%-11.82%5/7/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A6.85N/A-76.77%N/A-44.29%N/ALatest ARCT, AMPH, MRVI, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70N/AN/AN/A$173.46 millionN/A5/7/2026Q1 2026ARCTArcturus Therapeutics-$1.0133N/AN/AN/A$6.30 millionN/A5/7/2026Q1 2026MRVIMaravai LifeSciences-$0.05N/AN/AN/A$53.00 millionN/A3/3/2026Q4 2025ARCTArcturus Therapeutics-$0.92-$1.03-$0.11-$1.0230$14.32 million$7.20 million2/26/2026Q4 2025AMPHAmphastar Pharmaceuticals$0.97$0.73-$0.24$0.51$190.48 million$183.11 million2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 million2/25/2026Q4 2025MRVIMaravai LifeSciences-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.774.022.90ARCTArcturus TherapeuticsN/A6.646.64MRVIMaravai LifeSciences0.856.605.69PHATPhathom PharmaceuticalsN/A2.212.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%ARCTArcturus Therapeutics94.54%MRVIMaravai LifeSciences50.25%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%ARCTArcturus Therapeutics17.80%MRVIMaravai LifeSciences2.49%PHATPhathom Pharmaceuticals9.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.53 million31.35 millionOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableMRVIMaravai LifeSciences610257.07 million250.67 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableARCT, AMPH, MRVI, and PHAT HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineMay 5 at 1:19 PM | finance.yahoo.comHow The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksMay 5 at 1:35 AM | finance.yahoo.com147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.May 3, 2026 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)May 2, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)May 2, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 2, 2026 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?May 1, 2026 | marketbeat.comPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingMay 1, 2026 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPSApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings MissApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2026 | zacks.comPhathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comPhathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of EarningsApril 30, 2026 | finance.yahoo.comPhathom Pharmaceuticals (PHAT) Projected to Post Earnings on ThursdayApril 24, 2026 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?April 21, 2026 | marketbeat.comPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business ...April 20, 2026 | caledonianrecord.comCPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026April 20, 2026 | globenewswire.comAssessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder ReturnApril 17, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, AMPH, MRVI, and PHAT Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$23.90 +0.51 (+2.18%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$23.89 -0.01 (-0.04%) As of 05/6/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Arcturus Therapeutics NASDAQ:ARCT$9.13 +0.72 (+8.56%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$8.90 -0.23 (-2.52%) As of 05/6/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Maravai LifeSciences NASDAQ:MRVI$3.94 +0.09 (+2.34%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$3.94 0.00 (-0.13%) As of 05/6/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Phathom Pharmaceuticals NASDAQ:PHAT$12.67 +0.07 (+0.56%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$12.72 +0.05 (+0.43%) As of 05/6/2026 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
